Literature DB >> 12224050

Brain natriuretic peptide: role in cardiovascular and volume homeostasis.

Hemant Dhingra1, Chanwit Roongsritong, Neil A Kurtzman.   

Abstract

The identification of natriuretic peptides as key regulators of natriuresis and vasodilatation, and the appreciation that their secretion is under the control of cardiac hemodynamic and neurohumoral factors, has caused wide interest. The natriuretic peptides are structurally similar, but genetically distinct peptides that have diverse actions on cardiovascular, renal, and endocrine homeostasis. Atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP) are of myocardial cell origin, while cardiac natriuretic peptide (CNP) is of endothelial origin. ANP and BNP bind to the natriuretic peptide receptor (NPR-A) which, via 3' 5'-cyclic guanosine monophosphate (cGMP), mediates natriuresis, vasodialation, renin inhibition, and antimitogenic properties. CNP lacks natriuretic action but possesses vasodilating and growth inhibiting effects via the guanyl cyclase linked natriuretic peptide-B (NPR-B) receptor. All three peptides are cleared by natriuretic peptide-C receptor (NPR-C) and degraded by neutral endopeptidase, both of which are widely expressed in kidney, lung, and vascular wall. Recently, a fourth member of the natriuretic peptide, dendroaspsis natriuretic peptide (DNP) has been reported to be present in human plasma and atrial myocardium. Copyright 2002, Elsevier Science (USA). All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12224050     DOI: 10.1053/snep.2002.35666

Source DB:  PubMed          Journal:  Semin Nephrol        ISSN: 0270-9295            Impact factor:   5.299


  2 in total

1.  Origins of cardiac dysfunction in cirrhosis.

Authors:  W Jiménez; V Arroyo
Journal:  Gut       Date:  2003-10       Impact factor: 23.059

Review 2.  Assessing cardiovascular risk in children with chronic kidney disease. B-type natriuretic peptide: a potential new marker.

Authors:  Gema Ariceta; Ellen R Brooks; Craig B Langman
Journal:  Pediatr Nephrol       Date:  2005-08-05       Impact factor: 3.714

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.